Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer

Trial Profile

Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FIRE-3
  • Most Recent Events

    • 13 Dec 2018 Results (n=244) assessing published in the European Journal of Cancer.
    • 26 Nov 2018 Results assessing relevance Increased baseline carcinoembryonic antigen (CEA) serum level in n=356 patients, published in the European Journal of Cancer.
    • 05 Jun 2018 Results assessing association of efficacy with somatic DNA mutations, tumor mutational burden and MSI status in biomarker evaluable subpopulation (n =373) from this trial, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top